

POSTER PRESENTATION

Open Access

Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study

G Moyle^{1*}, C Orkin², M Fisher³, J Anderson⁴, J Dhar⁵, MH Wang⁶, J Ewan⁷

From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 7-11 November 2010

Background

Dyslipidemia in persons with HIV contributes significantly to cardiovascular (CV) risk. Abacavir (ABC) has been shown to increase lipid levels and some cohort studies have suggested an association between ABC use and myocardial infarction (MI). Comparative data suggested Truvada (TDF/FTC) has a lesser effect on lipid parameters than Kivexa [KVV]. We investigated the

change in fasting lipid parameters in hypercholesterolemic subjects switching from KVV + Efavirenz [EFV] to Atripla [ATR].

Methods

A 24-week, UK, open-label study in subjects stable on once daily (QD) KVV+EFV, HIV RNA <50 copies/mL for ≥6 months and fasting total cholesterol [TC] ≥5.2




Figure 1

¹Chelsea & Westminster Hospital, HIV/GU Medicine, London, UK
Full list of author information is available at the end of the article

mmol/L at screening, randomized to continue K VX +EFV or switch to QD ATR. The primary endpoint was change from baseline to Week 12 in fasting TC. Changes in fasting lipid parameters and 10 year risk score for coronary heart disease (CHD) were also assessed. At Week 12 subjects continuing on K VX+EFV were switched to ATR (delayed switch to ATR) and all subjects received ATR until Week 24.

Results

157 randomized subjects received at least 1 dose of study medication; 78 continued K VX+EFV, 79 switched to ATR at baseline; 69 switched to ATR at Week 12. Subjects were well matched for baseline characteristics. Figure 1.

At 12 weeks there was a significant reduction in TC, LDL, HDL and TG in the ATR arm ($p < 0.001$) and the ATR vs K VX+EFV between group difference ($p < 0.001$), which was confirmed for TC, LDL and HDL in the delayed switch to ATR arm after 12 weeks of switch. The mean (SD) change in 10-year risk for CHD was -0.6 (3.85) ATR vs -0.1 (2.69) K VX+EFV at Week 12 and -0.1 (3.68) in the delayed switch to ATR arm after 12 weeks of switch. There were no protocol defined virologic failures and no study drug related SAEs.

Conclusion

Switching from K VX+EFV to ATR led to a significant, rapid decline in lipid parameters and this may have had a positive impact on calculated CHD risk while maintaining virologic suppression. The full study results showed that the initial 12 week results were replicated in the delayed switch to ATR arm. These results confirm that ATR is a preferred treatment option to a K VX based regimen in hypercholesterolemic patients.

Author details

¹Chelsea & Westminster Hospital, HIV/GU Medicine, London, UK. ²St. Bartholomew's Hospital, HIV Department, London, UK. ³Royal Sussex County Hospital, The Lawson Unit, HIV Department, Brighton, UK. ⁴Homerton Hospital, Sexual Health Clinic, London, UK. ⁵Leicester Royal Infirmary, GU Medicine, Leicester, UK. ⁶Gilead Sciences, Biostatistics, Foster City, USA. ⁷Gilead Sciences Limited, Flowers Building, Granta Park, Cambridge, UK.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-P80

Cite this article as: Moyle et al.: Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):P80.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

